Does Medicare Cover Ozempic, Wegovy & Weight Loss Drugs?

Does Medicare cover Ozempic? It is one of the most searched Medicare questions of 2025 — and the answer depends entirely on why your doctor is prescribing it. Medicare Part D can cover Ozempic and similar GLP-1 drugs when they are prescribed for Type 2 diabetes, but Medicare does not cover those same drugs — or their weight-loss brand counterparts — when prescribed solely for obesity or weight management. Understanding that distinction could save you more than $1,000 a month.

This article explains the current coverage rules in plain language, breaks down the cost difference, covers what Medicare does pay for when it comes to weight management, and outlines the legislative changes that could reshape this picture in 2025 and 2026.

The Direct Answer: Same Drug, Different Coverage

The GLP-1 receptor agonist class includes some of the most transformative medications in recent decades. Two molecules dominate:

• Semaglutide — sold as Ozempic (diabetes) and Wegovy (obesity)
• Tirzepatide — sold as Mounjaro (diabetes) and Zepbound (obesity)

Here is how Medicare Part D treats each one:

The molecule is identical. The coverage is not. What drives this outcome is not clinical judgment — it is a statutory rule that has been in place since Medicare Part D launched in 2006.

Why Medicare Excludes Weight Loss Drugs

When Congress created Medicare Part D as part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, it wrote an explicit exclusion for certain drug categories into federal law. Under Social Security Act §1860D-2(e)(2)(A), Part D plans are prohibited from covering drugs used for anorexia, weight loss, or weight gain. This exclusion applies regardless of how clinically effective the drug is, how strongly a physician recommends it, or how significantly obesity impairs a patient’s quality of life.

That law predates Wegovy, Zepbound, and even Ozempic. It was written in an era when weight-loss drugs had weak evidence and significant safety concerns. The exclusion was not designed with GLP-1 agonists in mind — but it squarely captures them when their FDA-approved indication is weight management.

Because Wegovy’s FDA approval is specifically for chronic weight management in adults with a BMI of 30 or higher (or 27 or higher with at least one weight-related condition), Part D plans cannot legally cover it, even if they want to. The same applies to Zepbound.

Ozempic and Mounjaro, on the other hand, carry FDA approvals for glycemic control in Type 2 diabetes. When a physician prescribes them for that indication — and that is documented in the medical record — Part D plans are permitted to cover them, and most formularies do.

What This Costs Without Coverage

The retail price for GLP-1 drugs without insurance is steep:

• Ozempic (semaglutide): approximately $900–$1,000 per month
• Wegovy (semaglutide, higher dose): approximately $1,300–$1,400 per month
• Mounjaro (tirzepatide): approximately $1,000–$1,100 per month
• Zepbound (tirzepatide): approximately $900–$1,000 per month

For a Medicare beneficiary who does not have Type 2 diabetes and cannot obtain coverage through any other means, these prices are simply out of reach for most. Social Security retirement benefits average about $1,900 per month in 2025 — paying for a weight-loss drug at retail could consume more than half of that income.

The Cost Difference When Diabetes Coverage Applies

When a Part D plan covers Ozempic or Mounjaro for Type 2 diabetes, the picture changes dramatically. Under the Inflation Reduction Act’s $2,000 annual out-of-pocket cap for Medicare Part D (fully in effect as of 2025), a beneficiary’s total out-of-pocket spending on all Part D drugs in a calendar year cannot exceed $2,000. That cap applies to insulin, oral diabetes medications, and GLP-1 agonists for diabetes alike.

In practical terms, a beneficiary using Ozempic for diabetes management might pay:

• Tier 3 formulary copay: $40–$100 per fill, depending on the plan
• Annual out-of-pocket maximum: no more than $2,000 total for all Part D drugs
• With Extra Help (Low Income Subsidy): $0–$11 per fill (more on this below)

That is a difference of roughly $10,000–$16,000 per year compared to paying retail for an obesity indication. The financial stakes of the diabetes vs. obesity distinction are not academic — they are life-altering for beneficiaries on fixed incomes.

For a full explanation of how Part D cost-sharing works, including the out-of-pocket cap, see our guide to Medicare Part D.

If You Have Both Type 2 Diabetes and Obesity

This is the situation many Medicare beneficiaries actually face. Approximately 90 percent of people with Type 2 diabetes are overweight or obese, and GLP-1 drugs are clinically indicated for both conditions simultaneously.

If your physician prescribes Ozempic or Mounjaro for Type 2 diabetes, and you also happen to benefit from the weight-loss effect, that is legitimate. Part D will cover the drug for its diabetes indication regardless of whether weight loss is also an outcome. The key is the documented clinical indication in your medical record.

Practical Steps to Ensure Coverage

1. Talk to your physician explicitly. Ask whether your prescription documentation clearly states Type 2 diabetes as the indication. If your doctor is treating your diabetes and your weight together, the diabetes diagnosis should lead.
2. Check your plan’s formulary before filling. Use Medicare’s Plan Finder tool at medicare.gov or call your Part D plan directly to confirm Ozempic or Mounjaro is on the formulary and at what tier.
3. Request a formulary exception if needed. If your plan places the drug on a non-preferred tier or requires prior authorization, your doctor can submit clinical documentation to support an exception.
4. Document A1C levels and diabetes diagnosis in every refill request. Prior authorization for GLP-1 drugs often requires current lab values confirming active diabetes management.

For more detail on how Medicare handles diabetes medications across both Part B and Part D, see Medicare Coverage for Diabetes: CGMs, Insulin, Supplies, and More.

Medicare Advantage Plans: A Potential Alternative

Original Medicare (Parts A and B plus a standalone Part D plan) follows federal formulary law strictly. Medicare Advantage plans operate differently. While they must cover at minimum everything Original Medicare covers, they are permitted to offer supplemental benefits beyond the standard benefit — and some Medicare Advantage plans have begun covering GLP-1 drugs for obesity as a supplemental benefit.

Coverage varies significantly by plan and by region. As of 2025, a meaningful but still small minority of Medicare Advantage plans include GLP-1 obesity coverage. Here is how to investigate your options:

During Open Enrollment (October 15 – December 7)

1. Annual Notice of Change (ANOC): Every fall, your Medicare Advantage plan sends this document listing changes for the coming year. Review the formulary section specifically.
2. Plan formulary lookup: At medicare.gov/plan-compare, you can search plans by drug name. Enter “semaglutide” or “tirzepatide” and filter by obesity indication to find plans that cover it.
3. Call the plan directly: Ask specifically: “Does your plan cover Wegovy or Zepbound for chronic weight management in 2026?” Get the answer in writing.
4. Special Enrollment Periods: If you become eligible for a Special Enrollment Period (due to moving, losing other coverage, etc.), you may be able to switch plans outside the standard window.

Compare the full landscape of Medicare Advantage options in our guide to Medicare Advantage vs. Original Medicare.

What Medicare Does Cover for Weight Management

Even without GLP-1 coverage for obesity, Medicare does pay for evidence-based weight management services. Most beneficiaries are unaware of how comprehensive these benefits are.

Intensive Behavioral Therapy (IBT) for Obesity — Part B

This is one of the most underutilized preventive benefits in Medicare. Under 42 CFR §410.101, Medicare Part B covers Intensive Behavioral Therapy for obesity at no cost to the beneficiary (no copay, no coinsurance, no deductible) when delivered by a primary care physician in a primary care setting.

Who qualifies: Adults with a BMI of 30 or higher.

What is covered:

• Month 1: Weekly visits (up to 4 visits)
• Months 2–6: Every-other-week visits (up to 11 more visits)
• Months 7–12: Monthly visits (up to 6 more visits)
• Total Year 1: Up to 22 visits

If the patient loses at least 3 kg (6.6 lbs) in the first 6 months, Medicare continues to cover the monthly maintenance visits for the second 6 months. If they do not meet the weight-loss threshold, additional IBT visits are not covered that year.

Behavioral therapy for obesity addresses eating patterns, physical activity, and behavioral strategies — not medication. But for many beneficiaries, particularly those who cannot access GLP-1 drugs, these free visits with a primary care physician represent a meaningful, structured resource.

Bariatric Surgery — Parts A and B

Medicare covers bariatric surgery under Parts A and B (hospital and physician services) when specific criteria are met:

Coverage criteria:

• BMI of 40 or higher, regardless of comorbidities, OR
• BMI of 35 or higher with at least one obesity-related comorbidity (Type 2 diabetes, hypertension, sleep apnea, hyperlipidemia, or other documented conditions)

Covered procedures:

• Roux-en-Y gastric bypass (the most studied procedure with the strongest long-term evidence)
• Sleeve gastrectomy (increasingly favored due to lower complication rates vs. bypass)
• Adjustable gastric banding (still covered but rarely recommended given weaker long-term outcomes data and higher revision rates)

Surgery must be performed at a Medicare-approved bariatric surgery facility, and the surgeon must be credentialed for bariatric procedures. Your Part B deductible and 20 percent coinsurance apply (a Medigap policy would typically cover that coinsurance).

Nutritional Counseling — Part B

Medicare covers Medical Nutrition Therapy (MNT) for beneficiaries who have diabetes or chronic kidney disease. This includes up to three hours of individualized counseling with a registered dietitian or nutrition professional in the first year, and two hours per year thereafter. If your obesity is accompanied by Type 2 diabetes — which is common — this benefit adds another layer of structured support at no cost (after meeting the Part B deductible).

Extra Help / Low Income Subsidy

If you qualify for Extra Help (also called the Low Income Subsidy), and you are taking Ozempic or Mounjaro for Type 2 diabetes under a Part D plan, your cost-sharing drops dramatically:

• Full Extra Help: Copays of $0–$11 per prescription (exact amounts set annually by CMS)
• Partial Extra Help: Reduced premiums and cost-sharing based on income and assets

To qualify for Extra Help in 2025, income must be below approximately 150 percent of the Federal Poverty Level (about $21,600 for an individual). Assets generally must be below $16,600 for individuals or $33,240 for couples (2025 figures; these are updated annually).

Apply through Social Security at ssa.gov/extrahelp or call 1-800-772-1213. There is no fee to apply. For additional cost-reduction programs, including the Medicare Savings Programs that cover Part B premiums and cost-sharing, see Medicare Savings Programs.

The Legislative Landscape: What Might Change

The exclusion of weight-loss drugs from Medicare Part D has faced growing legislative pressure, particularly as semaglutide’s cardiovascular benefits have gained clinical traction.

The TREAT and ENRICH Acts

Two bills with bipartisan support have sought to lift the Part D weight-loss exclusion:

• The TREAT Act (Treating Obesity as a Disease Act): Would amend Social Security Act §1860D-2(e)(2)(A) to permit Part D coverage of FDA-approved obesity drugs. As of mid-2026, the bill has been introduced in both chambers but has not passed either.
• The ENRICH Act (Ensuring Nutrition and Reimbursement Increases for Chronic Health Act): Takes a narrower approach, focusing on coverage for beneficiaries with obesity-related cardiovascular disease. Also pending as of mid-2026.

Both bills face significant cost-scoring headwinds. The Congressional Budget Office has estimated that covering GLP-1 drugs for obesity under Part D could cost more than $35 billion over ten years, which has made passage difficult despite strong clinical and patient advocacy support.

CMS Proposed Rule on GLP-1 Coverage

In early 2025, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule that would allow Medicare Advantage and Part D plans to cover GLP-1 drugs for obesity as a supplemental benefit without counting them toward the statutory exclusion. The rule was designed to work within existing law by categorizing these drugs as cardiovascular-risk-reduction medications rather than weight-loss medications — a distinction supported by the SELECT trial (discussed below). The final rule’s status was still under review as of the publication date of this article; beneficiaries should monitor cms.gov for updates.

The SELECT Trial and Cardiovascular Indication

In 2023, semaglutide achieved something no weight-loss drug had before: it demonstrated a significant reduction in cardiovascular events (heart attack, stroke, cardiovascular death) in patients without diabetes who were overweight or obese. The SELECT trial, a large randomized controlled trial, showed a 20 percent relative risk reduction in major adverse cardiovascular events.

Based on that evidence, the FDA approved an additional indication for Wegovy in March 2024: reduction of cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight. This cardiovascular indication is meaningfully different from a weight-loss indication — and it has given CMS legal and clinical grounds to consider coverage through a different framework.

As the cardiovascular evidence base for these drugs continues to grow, the probability of broader Medicare coverage — whether through legislation, regulation, or a combination — appears to be increasing. Beneficiaries, particularly those with obesity and established heart disease, should watch for policy changes at the start of each plan year.

For more context on how Medicare costs and coverage gaps affect long-term financial planning, see Healthcare Costs in Retirement.

Frequently Asked Questions

Can my doctor prescribe Ozempic off-label for weight loss and have it covered by Medicare?

No. Even if your physician writes a prescription for semaglutide (Ozempic) and notes weight management as the purpose, Part D plans cannot cover it without an approved, on-label diabetes indication. Off-label prescribing does not override the statutory exclusion.

What if I switch from Ozempic to Wegovy at a higher dose for better weight loss results?

The moment the prescription switches to Wegovy — a drug with only an obesity FDA indication — Part D coverage ends. Even if the molecule is identical, the brand and indication matter for formulary purposes.

Does Medicare cover compounded semaglutide?

No. Compounded drugs are generally not covered by Medicare Part D, and CMS has scrutinized compounded GLP-1 drugs specifically. The FDA has also taken action against some compounding pharmacies for producing unapproved semaglutide formulations. Compounded options carry both coverage and safety risks.

My Medicare Advantage plan denied my GLP-1 claim. What can I do?

First, confirm whether the prescription is for a diabetes indication. If it is, and the drug is on your plan’s formulary, you have appeal rights. Request a coverage determination from the plan, then escalate to a redetermination and then a reconsideration by a Qualified Independent Contractor (QIC) if needed. Timelines and instructions must be provided in your denial notice.

Will Extra Help cover Wegovy if my state’s Medicaid program covers it?

Possibly. Some state Medicaid programs have broader obesity drug coverage than Medicare, and beneficiaries who are dual-eligible (both Medicare and Medicaid) should check with their state Medicaid office. However, Extra Help itself follows Part D formulary rules and cannot cover drugs that Part D excludes.

Summary: What to Do Now

1. If you have Type 2 diabetes: Talk to your physician about whether Ozempic or Mounjaro is appropriate for your diabetes management. Confirm the prescription documents your diabetes diagnosis as the primary indication. Check your Part D plan’s formulary and apply for Extra Help if your income qualifies.

2. If you have obesity but not diabetes: Ask your physician about Intensive Behavioral Therapy visits, which are free under Part B. If you’re considering Medicare Advantage, compare plans during open enrollment with an explicit focus on GLP-1 obesity coverage as a supplemental benefit. Monitor CMS and Congressional activity for coverage expansion.

3. If you have both: The diabetes indication covers the drug, and you benefit from both outcomes. Work with your care team to ensure documentation is clear and prior authorization requests are supported by current lab data.

4. If cost is a barrier even with Part D coverage: Apply for Extra Help through Social Security. Review the Medicare Savings Programs to reduce your overall Part D and Part B cost burden.

The landscape is changing. But as of mid-2026, the diabetes/obesity distinction remains the controlling rule. Knowing it — and navigating it strategically — is the most important thing a Medicare beneficiary can do on this issue today.